melatonin has been researched along with Fetal Growth Restriction in 32 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Adopting an integrative approach, by combining studies of cardiovascular function with those at cellular and molecular levels, this study investigated whether maternal treatment with melatonin protects against programmed cardiovascular dysfunction in the offspring using an established rodent model of hypoxic pregnancy." | 8.12 | Maternal melatonin: Effective intervention against developmental programming of cardiovascular dysfunction in adult offspring of complicated pregnancy. ( Blanco, CE; Camm, EJ; Galli, GLJ; Giussani, DA; Hansell, JA; Herrera, EA; Lock, MC; Patey, OV; Richter, HG; Trafford, AW; Villamor, E, 2022) |
| " Supplementing dietary melatonin during a compromised pregnancy increased uteroplacental blood flow and prevented IUGR in a seasonal-dependent manner." | 8.12 | Seasonal and temporal variation in the placenta during melatonin supplementation in a bovine compromised pregnancy model. ( Burnett, DD; Cochran, T; Contreras-Correa, ZE; Lemley, CO; Metcalfe, A, 2022) |
| "Placental insufficiency affects about 10% of pregnancies and can lead to pre-eclampsia, fetal growth restriction, and preterm birth." | 6.82 | The role of melatonin in pregnancies complicated by placental insufficiency: A systematic review. ( Bussolaro, S; Fantasia, I; Rolnik, DL; Stampalija, T, 2022) |
| "Fetal intrauterine growth restriction (IUGR) is a serious pregnancy complication associated with increased rates of perinatal morbidity and mortality, and ultimately with long-term neurodevelopmental impairments." | 6.79 | Antenatal antioxidant treatment with melatonin to decrease newborn neurodevelopmental deficits and brain injury caused by fetal growth restriction. ( Alers, NO; Castillo-Melendez, M; Drummond, GR; Jenkin, G; Loose, JM; Miller, SL; Sabaretnam, T; Supramaniam, VG; VanZyl, N; Walker, DW; Wallace, EM; Yawno, T, 2014) |
| "Melatonin is a powerful endogenous antioxidant." | 5.33 | Melatonin protects against lipopolysaccharide-induced intra-uterine fetal death and growth retardation in mice. ( Chen, YH; Sun, MF; Wang, H; Wang, JP; Wei, LZ; Wei, W; Xu, DX, 2006) |
| "Adopting an integrative approach, by combining studies of cardiovascular function with those at cellular and molecular levels, this study investigated whether maternal treatment with melatonin protects against programmed cardiovascular dysfunction in the offspring using an established rodent model of hypoxic pregnancy." | 4.12 | Maternal melatonin: Effective intervention against developmental programming of cardiovascular dysfunction in adult offspring of complicated pregnancy. ( Blanco, CE; Camm, EJ; Galli, GLJ; Giussani, DA; Hansell, JA; Herrera, EA; Lock, MC; Patey, OV; Richter, HG; Trafford, AW; Villamor, E, 2022) |
| " Supplementing dietary melatonin during a compromised pregnancy increased uteroplacental blood flow and prevented IUGR in a seasonal-dependent manner." | 4.12 | Seasonal and temporal variation in the placenta during melatonin supplementation in a bovine compromised pregnancy model. ( Burnett, DD; Cochran, T; Contreras-Correa, ZE; Lemley, CO; Metcalfe, A, 2022) |
| " In this scenario, melatonin acts as an umbilical vasodilator and a potent antioxidant that has not been evaluated in pregnancies under chronic hypoxia that induce fetal growth restriction." | 3.83 | Potential adverse effects of antenatal melatonin as a treatment for intrauterine growth restriction: findings in pregnant sheep. ( Araya, C; Ebensperger, G; González-Candia, A; Herrera, EA; Llanos, AJ; Quezada, S; Reyes, RV; Serón-Ferré, M; Veliz, M, 2016) |
| "Placental insufficiency affects about 10% of pregnancies and can lead to pre-eclampsia, fetal growth restriction, and preterm birth." | 2.82 | The role of melatonin in pregnancies complicated by placental insufficiency: A systematic review. ( Bussolaro, S; Fantasia, I; Rolnik, DL; Stampalija, T, 2022) |
| "Fetal intrauterine growth restriction (IUGR) is a serious pregnancy complication associated with increased rates of perinatal morbidity and mortality, and ultimately with long-term neurodevelopmental impairments." | 2.79 | Antenatal antioxidant treatment with melatonin to decrease newborn neurodevelopmental deficits and brain injury caused by fetal growth restriction. ( Alers, NO; Castillo-Melendez, M; Drummond, GR; Jenkin, G; Loose, JM; Miller, SL; Sabaretnam, T; Supramaniam, VG; VanZyl, N; Walker, DW; Wallace, EM; Yawno, T, 2014) |
| " This review details the adverse effects of IUGR on fetal brain development and discusses intervention strategies." | 2.53 | Neurodevelopment in children with intrauterine growth restriction: adverse effects and interventions. ( Fu, W; Liu, J; Wang, Y, 2016) |
| "Melatonin plays an important role in the sleep-wake cycle." | 2.53 | Effects of intrauterine growth restriction on sleep and the cardiovascular system: The use of melatonin as a potential therapy? ( Horne, RS; Miller, SL; Wallace, EM; Yiallourou, SR, 2016) |
| "Melatonin is a highly effective antioxidant, free radical scavenger, and has anti-inflammatory effect." | 2.48 | Melatonin utility in neonates and children. ( Chen, YC; Huang, LT; Sheen, JM; Tain, YL, 2012) |
| "Melatonin treatment of the chick embryo starting at day 13 of incubation, equivalent to ca." | 1.43 | Melatonin rescues cardiovascular dysfunction during hypoxic development in the chick embryo. ( Beck, C; Giussani, DA; Itani, N; Niu, Y; Skeffington, KL, 2016) |
| " In isolated neonatal coronary arteries, endothelium-dependent nitric oxide (NO) bioavailability was reduced in IUGR, and was rescued by modest melatonin treatment." | 1.40 | Maternal melatonin administration mitigates coronary stiffness and endothelial dysfunction, and improves heart resilience to insult in growth restricted lambs. ( Coleman, HA; Jenkin, G; Lim, R; Miller, SL; Parkington, HC; Sutherland, AE; Tare, M; Wallace, EM; Yawno, T, 2014) |
| "This melatonin-induced increase in umbilical artery blood flow may alter nutrient availability to the fetus, which may lead to alterations in fetal size." | 1.39 | Dietary melatonin supplementation alters uteroplacental amino acid flux during intrauterine growth restriction in ewes. ( Camacho, LE; Caton, JS; Kapphahn, M; Lemley, CO; Meyer, AM; Vonnahme, KA, 2013) |
| "Melatonin is a powerful endogenous antioxidant." | 1.33 | Melatonin protects against lipopolysaccharide-induced intra-uterine fetal death and growth retardation in mice. ( Chen, YH; Sun, MF; Wang, H; Wang, JP; Wei, LZ; Wei, W; Xu, DX, 2006) |
| "Melatonin secretion was estimated by analysing the overnight urinary excretion of 6-sulphatoxymelatonin." | 1.31 | The impact of fetal size and length of gestation on 6-sulphatoxymelatonin excretion in adult life. ( Cockington, RA; Flanagan, DE; Kennaway, DJ; Moore, VM; Phillips, DI; Robinson, JS, 2001) |
| "Melatonin (6 mg) was administered orally at 12:00 hr, and samples of chorion and maternal blood were obtained at the time of the procedure, 1, 2 or 3 hr later." | 1.31 | Melatonin stimulates glutathione peroxidase activity in human chorion. ( Fukaya, T; Kaneda, C; Okatani, Y; Shinohara, K; Wakatsuki, A, 2001) |
| "Melatonin could be useful in treating preeclampsia and possibly other clinical states involving excess free radical production, such as fetal growth restriction and fetal hypoxia." | 1.31 | Melatonin protects against oxidative mitochondrial damage induced in rat placenta by ischemia and reperfusion. ( Fukaya, T; Okatani, Y; Shinohara, K; Taniguchi, K; Wakatsuki, A, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.13) | 18.2507 |
| 2000's | 7 (21.88) | 29.6817 |
| 2010's | 15 (46.88) | 24.3611 |
| 2020's | 9 (28.13) | 2.80 |
| Authors | Studies |
|---|---|
| Hansell, JA | 1 |
| Richter, HG | 1 |
| Camm, EJ | 1 |
| Herrera, EA | 2 |
| Blanco, CE | 1 |
| Villamor, E | 1 |
| Patey, OV | 1 |
| Lock, MC | 1 |
| Trafford, AW | 1 |
| Galli, GLJ | 1 |
| Giussani, DA | 2 |
| Huang, C | 1 |
| Wu, D | 1 |
| Zhang, K | 1 |
| Khan, FA | 1 |
| Pandupuspitasari, NS | 1 |
| Wang, Y | 2 |
| Huo, L | 1 |
| Sun, F | 1 |
| Zhang, H | 1 |
| Liu, X | 1 |
| Zheng, Y | 1 |
| Zha, X | 1 |
| Elsabagh, M | 1 |
| Zhang, Y | 1 |
| Ma, Y | 1 |
| Loor, JJ | 1 |
| Wang, M | 1 |
| Wang, H | 3 |
| Fantasia, I | 1 |
| Bussolaro, S | 1 |
| Stampalija, T | 1 |
| Rolnik, DL | 1 |
| Contreras-Correa, ZE | 1 |
| Cochran, T | 1 |
| Metcalfe, A | 1 |
| Burnett, DD | 1 |
| Lemley, CO | 3 |
| Aynaoglu Yildiz, G | 1 |
| Yildiz, D | 1 |
| Yapca, OE | 1 |
| Suleyman, B | 1 |
| Arslan, YK | 1 |
| Kurt, N | 1 |
| Suleyman, H | 1 |
| Wang, D | 1 |
| Wu, X | 1 |
| Lu, D | 1 |
| Li, Y | 1 |
| Zhang, P | 1 |
| Ramos Gonzalez, M | 1 |
| DeConne, TM | 1 |
| Zhu, HL | 1 |
| Shi, XT | 1 |
| Xu, XF | 1 |
| Zhou, GX | 1 |
| Xiong, YW | 1 |
| Yi, SJ | 1 |
| Liu, WB | 1 |
| Dai, LM | 1 |
| Cao, XL | 1 |
| Xu, DX | 2 |
| Castillo-Melendez, M | 2 |
| Yawno, T | 4 |
| Sutherland, A | 1 |
| Jenkin, G | 4 |
| Wallace, EM | 6 |
| Miller, SL | 6 |
| Polglase, GR | 1 |
| Barbuto, J | 1 |
| Allison, BJ | 1 |
| Sutherland, AE | 2 |
| Malhotra, A | 1 |
| Schulze, KE | 1 |
| Ricardo, SD | 1 |
| Palmer, KR | 1 |
| Mockler, JC | 1 |
| Davies-Tuck, ML | 1 |
| Goergen, SK | 1 |
| Fahey, MC | 1 |
| Anderson, PJ | 1 |
| Groom, KM | 1 |
| Camacho, LE | 2 |
| Meyer, AM | 2 |
| Kapphahn, M | 1 |
| Caton, JS | 2 |
| Vonnahme, KA | 2 |
| Alers, NO | 1 |
| Supramaniam, VG | 1 |
| VanZyl, N | 1 |
| Sabaretnam, T | 1 |
| Loose, JM | 1 |
| Drummond, GR | 1 |
| Walker, DW | 1 |
| Tare, M | 1 |
| Parkington, HC | 1 |
| Lim, R | 1 |
| Coleman, HA | 1 |
| Fu, W | 1 |
| Liu, J | 1 |
| Yiallourou, SR | 1 |
| Horne, RS | 1 |
| Rodríguez-Rodríguez, P | 1 |
| de Pablo, AL | 1 |
| Condezo-Hoyos, L | 1 |
| Martín-Cabrejas, MA | 1 |
| Aguilera, Y | 1 |
| Ruiz-Hurtado, G | 1 |
| Gutierrez-Arzapalo, PY | 1 |
| Ramiro-Cortijo, D | 1 |
| Fernández-Alfonso, MS | 1 |
| González, Mdel C | 1 |
| Arribas, SM | 1 |
| Itani, N | 1 |
| Skeffington, KL | 1 |
| Beck, C | 1 |
| Niu, Y | 1 |
| Marseglia, L | 1 |
| D'Angelo, G | 1 |
| Manti, S | 1 |
| Reiter, RJ | 1 |
| Gitto, E | 1 |
| González-Candia, A | 1 |
| Veliz, M | 1 |
| Araya, C | 1 |
| Quezada, S | 1 |
| Ebensperger, G | 1 |
| Serón-Ferré, M | 1 |
| Reyes, RV | 1 |
| Llanos, AJ | 1 |
| Neville, TL | 1 |
| Newman, DJ | 1 |
| Chen, YC | 1 |
| Tain, YL | 1 |
| Sheen, JM | 1 |
| Huang, LT | 1 |
| Ma, N | 1 |
| Hardy, DB | 1 |
| Kennaway, DJ | 3 |
| Chen, YH | 1 |
| Wang, JP | 1 |
| Wei, LZ | 1 |
| Sun, MF | 1 |
| Wei, W | 1 |
| Nagai, R | 1 |
| Watanabe, K | 1 |
| Wakatsuki, A | 3 |
| Hamada, F | 1 |
| Shinohara, K | 3 |
| Hayashi, Y | 1 |
| Imamura, R | 1 |
| Fukaya, T | 3 |
| Goble, FC | 1 |
| Stamp, GE | 1 |
| Nakamura, Y | 1 |
| Tamura, H | 1 |
| Kashida, S | 1 |
| Takayama, H | 1 |
| Yamagata, Y | 1 |
| Karube, A | 1 |
| Sugino, N | 1 |
| Kato, H | 1 |
| Flanagan, DE | 1 |
| Moore, VM | 1 |
| Cockington, RA | 1 |
| Robinson, JS | 1 |
| Phillips, DI | 1 |
| Okatani, Y | 2 |
| Kaneda, C | 1 |
| Taniguchi, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot Study of Maternally Administered Melatonin to Decrease the Level of Oxidative Stress in Human Pregnancies Affected by Intrauterine Growth Restriction.[NCT01695070] | Phase 4 | 16 participants (Actual) | Interventional | 2012-09-30 | Completed | ||
| Melatonin for Neuroprotection Following Perinatal Asphyxia[NCT02071160] | Phase 1/Phase 2 | 45 participants (Actual) | Interventional | 2012-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 reviews available for melatonin and Fetal Growth Restriction
| Article | Year |
|---|---|
The role of melatonin in pregnancies complicated by placental insufficiency: A systematic review.
Topics: Antioxidants; Aspirin; Female; Fetal Growth Retardation; Humans; Infant, Newborn; Melatonin; Placent | 2022 |
Neurodevelopment in children with intrauterine growth restriction: adverse effects and interventions.
Topics: Adult; Antioxidants; Brain; Cerebral Palsy; Child; Cognition Disorders; Depression; Developmental Di | 2016 |
Effects of intrauterine growth restriction on sleep and the cardiovascular system: The use of melatonin as a potential therapy?
Topics: Antioxidants; Cardiovascular System; Child Development; Fetal Growth Retardation; Humans; Infant; In | 2016 |
Potential Utility of Melatonin in Preeclampsia, Intrauterine Fetal Growth Retardation, and Perinatal Asphyxia.
Topics: Animals; Antioxidants; Asphyxia Neonatorum; Female; Fetal Growth Retardation; Humans; Infant, Newbor | 2016 |
Melatonin utility in neonates and children.
Topics: Antioxidants; Child; Female; Fetal Growth Retardation; Humans; Hypoxia-Ischemia, Brain; Infant, Newb | 2012 |
The fetal origins of the metabolic syndrome: can we intervene?
Topics: Antioxidants; Ascorbic Acid; Diet Therapy; Dietary Supplements; Exenatide; Fatty Acids, Omega-3; Fem | 2012 |
Programming of the fetal suprachiasmatic nucleus and subsequent adult rhythmicity.
Topics: Animals; Birth Weight; Body Height; Circadian Rhythm; Drug-Related Side Effects and Adverse Reaction | 2002 |
2 trials available for melatonin and Fetal Growth Restriction
| Article | Year |
|---|---|
Protect-me: a parallel-group, triple blinded, placebo-controlled randomised clinical trial protocol assessing antenatal maternal melatonin supplementation for fetal neuroprotection in early-onset fetal growth restriction.
Topics: Adult; Antioxidants; Female; Fetal Growth Retardation; Humans; Infant; Male; Melatonin; Neuroprotect | 2019 |
Antenatal antioxidant treatment with melatonin to decrease newborn neurodevelopmental deficits and brain injury caused by fetal growth restriction.
Topics: Animals; Animals, Newborn; Antioxidants; Brain; Female; Fetal Growth Retardation; Humans; Melatonin; | 2014 |
23 other studies available for melatonin and Fetal Growth Restriction
| Article | Year |
|---|---|
Maternal melatonin: Effective intervention against developmental programming of cardiovascular dysfunction in adult offspring of complicated pregnancy.
Topics: Animals; Female; Fetal Growth Retardation; Hypoxia; Melatonin; Pregnancy; Pregnancy Complications; R | 2022 |
Perfluorooctanoic acid alters the developmental trajectory of female germ cells and embryos in rodents and its potential mechanism.
Topics: Animals; Caprylates; Female; Fetal Growth Retardation; Fluorocarbons; Germ Cells; Humans; Melatonin; | 2022 |
Effects of the maternal gut microbiome and gut-placental axis on melatonin efficacy in alleviating cadmium-induced fetal growth restriction.
Topics: Animals; Cadmium; Female; Fetal Growth Retardation; Gastrointestinal Microbiome; Humans; Melatonin; | 2022 |
Seasonal and temporal variation in the placenta during melatonin supplementation in a bovine compromised pregnancy model.
Topics: Animals; ARNTL Transcription Factors; Cattle; Cattle Diseases; Dietary Supplements; Female; Fetal Gr | 2022 |
Effect of diazepam, sertraline and melatonin on the stress-induced reproductive disorders and intrauterine growth restriction in female rats.
Topics: Animals; Antioxidants; Diazepam; Female; Fetal Growth Retardation; Melatonin; Oxidative Stress; Rats | 2021 |
The Melatonin and Enriched Environment Ameliorated Low Protein-Induced Intrauterine Growth Retardation by IGF-1 And mtor Signaling Pathway and Autophagy Inhibition in Rats.
Topics: Animals; Autophagy; Diet, Protein-Restricted; Disease Models, Animal; Female; Fetal Growth Retardati | 2021 |
Saying NO to fetal growth restriction: Implications for beetroot juice and melatonin.
Topics: Animals; Beta vulgaris; Blood Pressure; Female; Fetal Growth Retardation; Melatonin; Mice; Nitrates; | 2020 |
Melatonin protects against environmental stress-induced fetal growth restriction via suppressing ROS-mediated GCN2/ATF4/BNIP3-dependent mitophagy in placental trophoblasts.
Topics: Activating Transcription Factor 4; Adult; Animals; Case-Control Studies; Female; Fetal Growth Retard | 2021 |
Effects of Antenatal Melatonin Treatment on the Cerebral Vasculature in an Ovine Model of Fetal Growth Restriction.
Topics: Animals; Antioxidants; Brain; Female; Fetal Growth Retardation; Hypoxia-Ischemia, Brain; Melatonin; | 2017 |
Effects of antenatal melatonin therapy on lung structure in growth-restricted newborn lambs.
Topics: Animals; Animals, Newborn; Antioxidants; Female; Fetal Growth Retardation; Lung; Melatonin; Pregnanc | 2017 |
Dietary melatonin supplementation alters uteroplacental amino acid flux during intrauterine growth restriction in ewes.
Topics: Amino Acids; Animals; Blood Glucose; Chromatography, High Pressure Liquid; Dietary Supplements; Fema | 2013 |
Maternal melatonin administration mitigates coronary stiffness and endothelial dysfunction, and improves heart resilience to insult in growth restricted lambs.
Topics: Animals; Cardiotonic Agents; Coronary Circulation; Endothelium, Vascular; Female; Fetal Growth Retar | 2014 |
Fetal undernutrition is associated with perinatal sex-dependent alterations in oxidative status.
Topics: Animals; Animals, Newborn; Antioxidants; Biomarkers; Blood Pressure; Body Weight; Catalase; Disease | 2015 |
Melatonin rescues cardiovascular dysfunction during hypoxic development in the chick embryo.
Topics: Animals; Chick Embryo; Disease Models, Animal; Female; Fetal Growth Retardation; Humans; Melatonin; | 2016 |
Potential adverse effects of antenatal melatonin as a treatment for intrauterine growth restriction: findings in pregnant sheep.
Topics: Animals; Biomarkers; Birth Weight; Female; Fetal Development; Fetal Growth Retardation; Gestational | 2016 |
Melatonin supplementation alters uteroplacental hemodynamics and fetal development in an ovine model of intrauterine growth restriction.
Topics: Animal Nutritional Physiological Phenomena; Animals; Antioxidants; Dietary Supplements; Disease Mode | 2012 |
Melatonin protects against lipopolysaccharide-induced intra-uterine fetal death and growth retardation in mice.
Topics: Animals; Bone and Bones; Female; Fetal Death; Fetal Growth Retardation; Glutathione; Lipid Peroxidat | 2006 |
Melatonin preserves fetal growth in rats by protecting against ischemia/reperfusion-induced oxidative/nitrosative mitochondrial damage in the placenta.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Deoxyguanosine; DNA Damage; DNA-(Apurinic or Apyrimidinic Site | 2008 |
Factors influencing the development of melatonin rhythmicity in humans.
Topics: Birth Weight; Cesarean Section; Female; Fetal Growth Retardation; Fetal Membranes, Premature Rupture | 1996 |
Changes of serum melatonin level and its relationship to feto-placental unit during pregnancy.
Topics: Adult; Circadian Rhythm; Female; Fetal Growth Retardation; Humans; Melatonin; Pre-Eclampsia; Pregnan | 2001 |
The impact of fetal size and length of gestation on 6-sulphatoxymelatonin excretion in adult life.
Topics: Adult; Birth Weight; Body Mass Index; Embryonic and Fetal Development; Female; Fetal Growth Retardat | 2001 |
Melatonin stimulates glutathione peroxidase activity in human chorion.
Topics: Abortion, Induced; Chorion; Enzyme Activation; Female; Fetal Growth Retardation; Free Radical Scaven | 2001 |
Melatonin protects against oxidative mitochondrial damage induced in rat placenta by ischemia and reperfusion.
Topics: Adenosine Diphosphate; Animals; Female; Fetal Growth Retardation; Humans; Melatonin; Mitochondria; O | 2001 |